See the DrugPatentWatch profile for vascepa

Vascepa is a prescription medication that contains the active ingredient icosapent ethyl, and it is primarily used to reduce triglyceride levels in adults with severe hypertriglyceridemia. Statins, on the other hand, are a class of drugs commonly used to lower cholesterol levels. To determine if there are any potential interactions between Vascepa and statins, we will examine the provided sources.

Upon reviewing the sources, it is important to note that the first source, DrugPatentWatch, provides information about the patent status of Vascepa and does not specifically mention any drug interactions. The second source, Medical News Today, provides general information about Vascepa, but it does not discuss any potential interactions with statins. The third source, the FDA label for Vascepa, contains comprehensive information about the medication, including potential drug interactions.

According to the FDA label for Vascepa, there are no specific drug-drug interaction studies conducted with statins. However, it does mention that concomitant use of Vascepa with known inhibitors of CYP3A4 and CYP2C8 may increase the exposure to the active metabolite of Vascepa. This is important because some statins, such as simvastatin and lovastatin, are metabolized by CYP3A4, which means that there is a theoretical possibility of an interaction. Increased exposure to the active metabolite of Vascepa may potentially increase the risk of adverse effects.

It is important to consult with a healthcare professional or pharmacist for personalized advice regarding potential drug interactions between Vascepa and statins. They will have access to your complete medical history and can provide guidance based on your specific situation.

In summary, while there is no specific information about interactions between Vascepa and statins in the provided sources, the FDA label for Vascepa mentions the potential for increased exposure to the active metabolite of Vascepa when used concomitantly with known inhibitors of CYP3A4 and CYP2C8. Therefore, it is recommended to consult with a healthcare professional for personalized advice.

Sources:
[1] DrugPatentWatch - https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] Medical News Today - https://www.medicalnewstoday.com/articles/drugs-vascepa
[3] FDA Label for Vascepa - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/202057s035lbl.pdf